TOP > 外国特許検索 > CREATION OF PEPTIDE-BASED ANTI-TUMOR AGENT

CREATION OF PEPTIDE-BASED ANTI-TUMOR AGENT NEW

外国特許コード F190009947
整理番号 (S2018-0332-N0)
掲載日 2019年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP003482
国際公開番号 WO 2019151439
国際出願日 平成31年1月31日(2019.1.31)
国際公開日 令和元年8月8日(2019.8.8)
優先権データ
  • 特願2018-015606 (2018.1.31) JP
発明の名称 (英語) CREATION OF PEPTIDE-BASED ANTI-TUMOR AGENT NEW
発明の概要(英語) The purpose of the present invention is to provide an echinomycin derivative having anti-cancer activity equal to or greater than that of echinomycin, and a production method therefor based on a chemical procedure. Provided are an echinomycin derivative represented by formula (I), and a production method therefor based on a chemical procedure.
従来技術、競合技術の概要(英語) BACKGROUND ART
Cancer is more up to date Shouwa 56th, the leading cause of death of Japanese and, new therapies are always required. As a method of treating cancer, surgery, radiation therapy, chemotherapy and the like (the anti-cancer agent), in particular anti-cancer agent, and may be used together with other widely used. As anti-cancer agents, alkylating agents, antimetabolites, anti-cancer agent alkaloid, antibiotic anti-cancer agents, such as platinum is used in the formulation, although the therapeutic effect is not yet sufficient, the problem that the occurrence of side effects and a high frequency, the development of better anti-cancer agent is demanded.
Echinomycin is, in the year 1957 in actinomycetes Streptomyces, ekinatasu cyclic peptides (Streptomyces echinatus) isolated from a natural system. Echinomycin is, in vivo and in vitro anti-cancer activity is strong in that have been identified. In the United States, echinomycin is an effective component of the first anti-cancer agent in clinical trials was 2 phase (non-patent document 1), because of the toxicity observed in clinical development is then canceled.
However, in recent years, echinomycin is HIF-1a have inhibitory activity (non-patent document 2) revealed, further, echinomycin to low doses administered cancer stem cell when the cell growth inhibitory activity selected, such as pancreatic cancer and the treatment of acute myeloid leukemia have been reported to be effective (non-patent document 3, Non-Patent Document 4). For this reason, attention is again and echinomycin, to thereby control the dose in the clinical trial to resume has been studied also.
On the other hand, the manufacture of echinomycin, the biosynthesis of microorganisms depends on the method based on the, chemical production processes has not been developed. In addition, obtained from microorganisms and echinomycin, chemically modifying the known method, echinomycin derivative is synthesized thus far, an anti-cancer activity compared with echinomycin was lowered in the well.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • HOKKAIDO UNIVERSITY
  • ASAHIKAWA MEDICAL UNIVERSITY
  • 発明者(英語)
  • ICHIKAWA, Satoshi
  • KOJIMA Keita
  • FUJIYA Mikihiro
  • KONISHI Hiroaki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください

PAGE TOP

close
close
close
close
close
close